The study of cancer genes has traditionally relied on genetically-engineered mouse strains made via transgenesis or gene targeting in embryonic stem (ES) cells. Our goals is to explore various small RNA tools to functionally dissect cancer mutations in mouse models of liver cancer and lung cancer. Learn more about our lab, work, discoveries and publications.
We are using the CRISPR/Cas system in vivo to build new cancer models by directly targeting tumor suppressor genes or inducing gain-of-function mutations of oncogenes in somatic cells. This presents a new avenue for rapid development of cancer models, functional genomics and proof-of-concept disease gene repair. Read more
Our research paper "Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo" is already published.
“This finding really excites us because it makes us think that this is a gene repair system that could be used to treat a range of diseases — not just tyrosinemia but others as well,” says Dr. Daniel Anderson.“It’s really exciting to see our team develop this new delivery approach for CRISPR, which I believe has the potential to have far-reaching implications,” says Dr. Robert Langer. Read more
